Xagrid (anagrelide hydrochloride) - Important Safety Information from Takeda Products Ireland Limited as approved by the HPRA (22.02.2022)

Notice type: Advisory

Date: 28/02/2022




Problem Or Issue:

Important Safety Information from Takeda Products Ireland Limited regarding Xagrid (anagrelide hydrochloride): Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation

Important Safety Information – Xagrid (anagrelide hydrochloride)




« Back